Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by Johnson & Johnson), Coley Pharmaceutical Group (IPO/ acquired by Pfizer), Genetics Institute (IPO/ acquired by Wyeth), Icagen (IPO/ acquired by Pfizer), IDEC Pharmaceuticals (IPO/ merged with Biogen), IDEXX Laboratories (NASDAQ: IDXX), Millennium Pharmaceuticals (IPO/acquired by Takeda) and Sepracor (IPO/acquired by Dainippon Sumitomo). More than 30 of his investments have been through an IPO during his Venrock tenure.
Tony started his career as a Research Scientist and Group Leader in Organic Chemistry at Union Carbide and as Director of Product Development at Story Chemical. He serves as a Trustee of The Jackson Laboratory, as a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, as a Director of the New York Genome Center, as a Chairman of the Albert and Mary Lasker Foundation, and as a Trustee Emeritus of Princeton University and The Rockefeller University. Tony is focused on building valuable companies that address important medical needs of the world, while providing strong returns for investors.
Tony received his A.B. in Chemistry from Princeton University and his Ph.D. in Chemistry from the Massachusetts Institute of Technology.